These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15497579)

  • 1. The cost of cardiac arrest in the workplace.
    Ambrose R
    Occup Health Saf; 2004 Sep; 73(9):88, 90, 202. PubMed ID: 15497579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

  • 3. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercholesterolemia: the cost of treatment in perspective.
    Kelley MD
    South Med J; 1990 Dec; 83(12):1421-5. PubMed ID: 2174577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The price of pain in the workplace.
    McCaffrey E
    Bus Health; 1996 Nov; 14(11 Suppl A):8-11, 30. PubMed ID: 10162916
    [No Abstract]   [Full Text] [Related]  

  • 6. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Apr; 99(7):1013-5. PubMed ID: 17398203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How health promotion outweighed STD costs.
    Serxner S; Gold D
    Bus Health; 2001 Jun; 19(6):25-8. PubMed ID: 11434095
    [No Abstract]   [Full Text] [Related]  

  • 8. [Health screening in the workplace. Benefits and principles].
    Rasmussen K; Lunde-Jensen P; Svane O
    Ugeskr Laeger; 1990 Oct; 152(43):3144-8. PubMed ID: 2238192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.
    Reynolds TM
    J Tissue Viability; 2008 Nov; 17(4):115-20. PubMed ID: 19061825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of antihypertensive drugs: a perspective on medical innovation.
    Cutler DM; Long G; Berndt ER; Royer J; Fournier AA; Sasser A; Cremieux P
    Health Aff (Millwood); 2007; 26(1):97-110. PubMed ID: 17211019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Costs of occupational diseases and accidents at work in Poland].
    Rydlewska-Liszkowska I
    Med Pr; 2006; 57(4):317-24. PubMed ID: 17133912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Employer costs of alcohol-involved injuries.
    Zaloshnja E; Miller TR; Hendrie D; Galvin D
    Am J Ind Med; 2007 Feb; 50(2):136-42. PubMed ID: 17187380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Models of workers' health and safety insurance in the selected European Union member states: certain economic problems].
    Rydlewska-Liszkowska I
    Med Pr; 2007; 58(6):511-9. PubMed ID: 18421933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of training unselected laypersons in cardiopulmonary resuscitation and defibrillation.
    Groeneveld PW; Owens DK
    Am J Med; 2005 Jan; 118(1):58-67. PubMed ID: 15639211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-country health-economic evaluation of highly concentrated n-3 polyunsaturated fatty acids in the secondary prevention after myocardial infarction.
    Lamotte M; Annemans L; Kawalec P; Zoellners Y
    Herz; 2006 Dec; 31 Suppl 3():74-82. PubMed ID: 17575809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
    Miller TR; Zaloshnja E; Spicer RS
    Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient lift teams: effective strategy to reduce back injuries and related costs.
    Healthc Hazard Manage Monit; 2005 May; 18(9):1-6. PubMed ID: 15926383
    [No Abstract]   [Full Text] [Related]  

  • 20. Estimation of net-costs for prevention of occupational low back pain: three case studies from the US.
    Lahiri S; Gold J; Levenstein C
    Am J Ind Med; 2005 Dec; 48(6):530-41. PubMed ID: 16299707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.